Literature DB >> 2940242

Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan.

J A Marcum, D H Atha, L M Fritze, P Nawroth, D Stern, R D Rosenberg.   

Abstract

Cloned bovine aortic endothelial cells were cultured with [35S]Na2SO4 and proteolyzed extensively with papain. Radiolabeled heparan sulfate was isolated by DEAE-Sephacel chromatography. The mucopolysaccharide was then affinity fractionated into two separate populations utilizing immobilized antithrombin. The heparan sulfate, which bound tightly to the protease inhibitor, represented 0.84% of the mucopolysaccharide mass, accounted for greater than 99% of the initial anticoagulant activity, and exhibited a specific activity of 1.16 USP units/10(6) 35S-cpm. However, the heparan sulfate that interacted minimally with the protease inhibitor constituted greater than 99% of the mucopolysaccharide mass, represented less than 1% of the starting biologic activity, and possessed a specific anticoagulant potency of less than 0.0002 USP unit/10(6) 35S-cpm. An examination of the disaccharide composition of the two populations revealed that the high-affinity heparan sulfate contained a 4-fold or greater amount of GlcA----GlcN-SO3-3-O-SO3 (where GlcA is glucuronic acid), which is a marker for the antithrombin-binding domain of commercial heparin, as compared with the depleted material. Cloned bovine aortic endothelial cells were incubated with [35S]Na2SO4 as well as tritiated amino acids and completely solubilized with 4 M guanidine hydrochloride and detergents. The double-labeled proteoglycans were isolated by DEAE-Sephacel, Sepharose CL-4B, and octyl-Sepharose chromatography. These hydrophobic macromolecules were then affinity fractionated into two separate populations utilizing immobilized antithrombin. The heparan sulfate proteoglycans which bound tightly to the protease inhibitor represented less than 1% of the starting material and exhibited a specific anticoagulant activity as high as 21 USP units/10(6) 35S-cpm, whereas the heparan sulfate proteoglycan that interacted weakly with the protease inhibitor constituted greater than 99% of the starting material and possessed a specific anticoagulant potency as high as 0.02 USP unit/10(6) 35S-cpm. The high-affinity heparan sulfate proteoglycan is responsible for more than 85% of the anticoagulant activity of the cloned bovine aortic endothelial cells. Binding studies conducted with 125I-labeled antithrombin demonstrated that these biologically active proteoglycans are located on the surface of cloned bovine aortic endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940242

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  73 in total

Review 1.  Heparan sulfate: antithrombotic or not?

Authors:  Jeffrey I Weitz
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

2.  Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis.

Authors:  Sassan HajMohammadi; Keiichi Enjyoji; Marc Princivalle; Patricia Christi; Miroslav Lech; David Beeler; Helen Rayburn; John J Schwartz; Samad Barzegar; Ariane I de Agostini; Mark J Post; Robert D Rosenberg; Nicholas W Shworak
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

3.  Molecular cloning of amphiglycan, a novel integral membrane heparan sulfate proteoglycan expressed by epithelial and fibroblastic cells.

Authors:  G David; B van der Schueren; P Marynen; J J Cassiman; H van den Berghe
Journal:  J Cell Biol       Date:  1992-08       Impact factor: 10.539

4.  Cell mutants defective in synthesizing a heparan sulfate proteoglycan with regions of defined monosaccharide sequence.

Authors:  A L De Agostini; H K Lau; C Leone; H Youssoufian; R D Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

5.  Heparin treatment of vascular smooth muscle cells results in the synthesis of the dual-specificity phosphatase MKP-1.

Authors:  Cheryl Isleib Blaukovitch; Raymond Pugh; Albert C Gilotti; Daniela Kanyi; Linda J Lowe-Krentz
Journal:  J Cell Biochem       Date:  2010-05-15       Impact factor: 4.429

Review 6.  Which anti-platelet therapies might be beneficial in xenotransplantation?

Authors:  Moritz Schmelzle; Peter J Cowan; Simon C Robson
Journal:  Xenotransplantation       Date:  2011 Mar-Apr       Impact factor: 3.907

Review 7.  Mice deficient in heparan sulfate 3-O-sulfotransferase-1: normal hemostasis with unexpected perinatal phenotypes.

Authors:  Nicholas W Shworak; Sassan HajMohammadi; Ariane I de Agostini; Robert D Rosenberg
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

8.  Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors.

Authors:  D Kirchhofer; T B Tschopp; P Hadváry; H R Baumgartner
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

9.  Human follicular fluid heparan sulfate contains abundant 3-O-sulfated chains with anticoagulant activity.

Authors:  Ariane I de Agostini; Ji-Cui Dong; Corinne de Vantéry Arrighi; Marie-Andrée Ramus; Isabelle Dentand-Quadri; Sébastien Thalmann; Patricia Ventura; Victoria Ibecheole; Felicia Monge; Anne-Marie Fischer; Sassan HajMohammadi; Nicholas W Shworak; Lijuan Zhang; Zhenqing Zhang; Robert J Linhardt
Journal:  J Biol Chem       Date:  2008-07-31       Impact factor: 5.157

Review 10.  Albuminuria reflects widespread vascular damage. The Steno hypothesis.

Authors:  T Deckert; B Feldt-Rasmussen; K Borch-Johnsen; T Jensen; A Kofoed-Enevoldsen
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.